Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 1;25(1):27-32.
doi: 10.1093/ibd/izy205.

Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD

Joseph A Picoraro  1 , Dale Lee  2 , Caren A Heller  3 , Alandra Weaver  3 , Jeffrey S Hyams  4 , Laurie S Conklin  5   6 , Anthony Otley  7 , David Ziring  8 , Subra Kugathasan  9 , Joel R Rosh  10 , Andrew Mulberg  11 , Lee A Denson  12 , Michael D Kappelman  13 , Andrew B Grossman  14 , Athos Bousvaros  15 , K T Park  16
Affiliations

Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD

Joseph A Picoraro et al. Inflamm Bowel Dis. .

Abstract

The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.10.1093/ibd/izy205_video1izy205.video15799266615001.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Opportunities to advance pharmacotherapies in pediatric IBD. Standardized measures include acvity indices, patient-reported outcomes, endoscopic score. Abbreviations: pD, pharmacodynamic; PhII, phase 2; PhIII, phase 3; pK, pharmacokine c.
FIGURE 2.
FIGURE 2.
Opportunities to develop infrastructure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28:445–458. - PubMed
    1. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America , Bousvaros A, et al. . Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–674. - PubMed
    1. Griffiths AM, Otley AR, Hyams J, et al. . A review of activity indices and end points for clinical trials in children with Crohn’s disease. Inflamm Bowel Dis. 2005;11:185–196. - PubMed
    1. Turner D, Otley AR, Mack D, et al. . Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–432. - PubMed
    1. Bousvaros A, Sylvester F, Kugathasan S, et al. ; Challenges in Pediatric IBD Study Groups . Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:885–913. - PubMed

Publication types

MeSH terms

Substances